What to ask before you agree to a clinical study at your hospital

Why the invitation matters more than it seems

A physician gets approached to join a clinical study almost every year of practice. Sometimes it's a device maker, sometimes a research coordinator from a larger academic center, sometimes a colleague who already signed on and wants a second site. The pitch usually sounds simple: enroll a few patients, follow a protocol, collect some data. What gets left out is how much staff time, workflow disruption, and long-term reputational exposure comes attached to that "simple" ask.

Before signing on as a site or a principal investigator, there's a short list of questions worth working through. None of them require a legal background. They just require slowing down before the enthusiasm of a new opportunity takes over.

Who actually owns the data

Ask, in plain terms, who controls the dataset once it's collected. Is it the sponsor, the institution, or shared? This matters because it determines whether you can publish independently, whether you'll see results before they're released publicly, and whether your name stays attached to conclusions you didn't help write. Physicians sometimes assume that because they enrolled patients, they have a say in how the results get framed. That's not always true, and the study agreement is the only place this gets settled.

What the real time cost looks like

Every protocol document underestimates the time it takes to screen, consent, and follow a patient correctly. Ask for the actual per-patient time estimate from someone who has run the specific protocol before, not just the sponsor's projected average. Coordinator hours, extra imaging visits, and paperwork for adverse event reporting all add up quietly. A study that looks like a two-hour-a-week commitment on paper often runs closer to five or six once you count the administrative side.

Who is covering the cost of what isn't reimbursed

Clinical trials rarely cover every cost tied to patient care. Ask specifically what happens if a patient needs a complication managed outside the protocol, or if a procedure runs longer than billed for. Some sponsors build in a contingency budget. Many don't, and the site quietly absorbs the difference. Get this in writing rather than relying on a verbal assurance from a study coordinator who may not control the budget.

What the exit looks like

Every study should have a clear answer to: what happens if we want to stop enrolling halfway through? Sites sometimes discover, only after committing, that pulling out mid-study creates data problems for the sponsor, and that this friction gets treated as a breach of the relationship rather than a normal business decision. Ask up front what the notice period is and what obligations continue after a site withdraws.

Whether the endpoint answers a question you actually have

This one gets skipped the most often. Before agreeing to participate, ask whether the primary endpoint measures something that changes practice, or something that mainly helps a regulatory submission move forward. Both are legitimate reasons to run a study. The problem comes when a physician signs on assuming the former and later realizes the trial was built around the latter. This isn't dishonesty on the sponsor's part. It's a mismatch that a five-minute conversation up front would have caught.

David Ferrera, who has spent nearly 30 years developing medical devices and building companies in interventional radiology and neurovascular medicine, has seen this mismatch play out from the sponsor side as well as the site side. The physicians who ask about endpoints before enrolling their first patient tend to have a much smoother study than the ones who ask after.

A clear conversation early on tends to serve both sides better than a vague one. Sponsors are managing their own set of constraints too, and physicians who ask direct questions about endpoints and expectations up front usually get more direct answers in return.

What support actually exists day to day

Ask who answers the phone when something goes wrong at 6 p.m. on a Friday. Is there a real clinical liaison, or does every question route through a shared inbox with a two-day response time? This detail rarely comes up in the initial pitch meeting, but it determines how smoothly the study runs once enrollment starts.

A short list to bring to the first meeting

• Who owns the data and who approves publications
• What the realistic per-patient time cost is, from someone who has run this exact protocol
• What isn't reimbursed, and who absorbs that cost
• What the withdrawal process looks like, in writing
• Whether the endpoint matches a real clinical question
• Who provides day-to-day support once the study is live

None of these questions signal distrust. They signal that a physician takes the commitment seriously enough to understand it fully before saying yes. Sponsors who are running a well-organized study will have straightforward answers ready. The ones who hesitate on basic logistics are telling you something too.